Seattle Genetics gets sector perform by RBC

RBC Capital Markets analyst Jason Kantor reiterated Seattle Genetics, Inc. at sector perform, above average risk, with a $6 price target, on expectations of modest forecast news flow and the start of pivotal trials for SGN-40 in 2007. Kantor believes improved stock performance in 2007 may be linked to increased visibility on the regulatory path for SGN-40, new partnerships, and proof of concept for next-generation antibody/drug conjugates. Shares of the Bothell, Wash.-based biotechnology company were unchanged at $4.82. (Nasdaq: SGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.